GLP-1 Agonists Show Potential to Slow Progression of Wolfram Syndrome

Wolfram syndrome is a severe, rare genetic disorder characterized by juvenile-onset diabetes mellitus, progressive optic atrophy (vision loss), diabetes insipidus, and profound neurodegeneration. It stems from mutations in the WFS1 gene, leading to cellular stress, particularly within the endoplasmic reticulum, and mitochondrial dysfunction, which are critical for cell survival and function. Current therapeutic approaches are largely symptomatic, failing to address the underlying disease progression or offer a cure. This study investigates whether GLP-1 receptor agonists, known for their metabolic and neuroprotective properties, can offer a disease-modifying strategy for Wolfram syndrome patients.